Loading
Loading
Research Overview
Mitochondria-derived peptide encoded in the 16S rRNA region of mtDNA; activates formyl peptide receptor-like 1 and GP130 receptors to exert cytoprotective, anti-apoptotic, and insulin-sensitising effects; associated with metabolic and neuroprotective signalling.
Humanin is a mitochondria-encoded peptide that has been investigated extensively in preclinical research as a regulator of cellular stress responses. First identified in experimental screens for factors that attenuate neuronal cell death, Humanin is now recognized as a member of the broader class of mitochondrial-derived peptides involved in intracellular and intercellular signaling. The peptide is composed of 24 amino acids and is encoded within the mitochondrial 16S ribosomal RNA gene, distinguishing it from nuclear-encoded signaling peptides.
Across in vitro systems and animal models, Humanin has been examined for its interactions with apoptotic regulators, mitochondrial membranes, and cell-surface receptor complexes. Experimental findings indicate that Humanin can bind pro-apoptotic proteins within cells while also activating survival-associated signaling pathways when acting extracellularly. These mechanisms have been studied in neuronal, cardiac, endothelial, pancreatic, and metabolic research models subjected to oxidative, ischemic, inflammatory, or metabolic stress.Humanin levels have been observed to change with age and metabolic status in experimental organisms, and altered expression has been reported in multiple disease-associated animal models. Stabilized Humanin analogs have been developed to enhance experimental potency and persistence in preclinical settings. All observations described are derived exclusively from non-clinical research. No human trials have established safety, pharmacokinetics, dosing parameters, or therapeutic relevance, and all findings remain investigational.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, humanin has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Humanin research is most relevant to protocols examining:
Mitochondria-derived peptide (MOTS-c, Humanin) biology research
Neuroprotective signalling and cognitive decline prevention studies
Insulin sensitisation and metabolic health investigations
Anti-apoptotic cytoprotection research
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Mitochondria-derived peptide encoded in the 16S rRNA region of mtDNA; activates formyl peptide receptor-like 1 and GP130 receptors to exert cytoprotective, anti-apoptotic, and insulin-sensitising effects; associated with metabolic and neuroprotective signalling.
| Parameter | Value |
|---|---|
| Dose range | 2–5 mg/week |
| Schedule | 2–3× per week |
| Route | Subcutaneous, Intranasal |
| Half-life | ~Hours |
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.